27 C
Vientiane
Saturday, April 26, 2025
spot_img
Home Blog Page 15

Theo Raises $20M to Democratize Access to Institutional-Grade Trading Infrastructure

Founded by ex-Optiver and IMC quants, the platform is backed by angels from Citadel, Jane Street, and JPMorgan

NEW YORK, April 25, 2025 /PRNewswire/ — Theo, a novel network connecting onchain capital to global markets via institutional-grade trading infrastructure, today announced it has raised $20 million in funding. The round was jointly led by Hack VC and Anthos Capital, with participation from numerous other venture capital firms, including Manifold Trading, Mirana Ventures, Metalayer Ventures, Flowdesk, SCB, MEXC, Amber Group, and Selini Capital, as well as angels from a range of leading TradFi trading firms including Citadel, Jane Street, HRT, Optiver, IMC, 5 Rings, and JPMorgan. 

Founded by former quant traders; Abhi Pingle, Arijit Pingle, and TK Kwon who honed their expertise at elite trading firms Optiver and IMC Trading, Theo was born from a recognition: while onchain capital is growing exponentially, access to traditional and institutional-grade strategies remain out of reach for everyday users. Theo aims to bridge this gap – delivering the sophistication of Wall Street to the retail investor.

Theo’s platform provides access to institutional-grade trading infrastructure that supports a wide range of strategies traditionally reserved for hedge funds and proprietary trading firms. At its core, Theo operates a custom low-latency validator set that ensures custodial guarantees for users, while enforcing rule-based access for institutional counterparties like market makers and trading firms.

These validators facilitate real-time execution across centralized exchanges (CEXes) and decentralized protocols (DeFi), while enforcing margin requirements and maintaining system-wide overcollateralization. Retail users can access these strategies via a simple deposit into strategy-specific vaults—without the complexity of multiple exchange accounts or algorithmic trading knowledge.

“Today’s crypto markets are fragmented and inefficient, preventing institutions and everyday users alike from accessing the full promise of global, permissionless finance,” says Abhi Pingle, co-founder of Theo. “Theo solves this by delivering robust, scalable infrastructure that seamlessly connects large traditional players and retail participants on-chain—unlocking new levels of capital efficiency.”

Theo strategies allow anyone to passively access professional trading strategies by simply depositing assets, with the platform handling execution, risk, and dynamic capital allocation across approaches like high-frequency arbitrage, cross-chain funding rate optimization, and advanced hedging.

As market conditions shift, Theo’s infrastructure dynamically reallocates capital to maintain performance, where single-strategy platforms often see returns diminish. This flexibility ensures greater stability and performance for retail participants.

For trading firms, Theo enables superior capital efficiency. By leveraging user capital through vault participation, firms can cross-margin strategy positions against their proprietary trades—unlocking alpha while users share in the upside. This creates a mutually beneficial ecosystem: institutional-grade strategies, retail accessibility, and shared value creation.

Theo’s architecture is uniquely positioned to connect traditional and crypto-native financial venues. As the industry evolves, Theo’s role as an infrastructure layer will be instrumental in bridging legacy markets and the onchain economy—democratizing access to advanced financial tools worldwide.

About Theo

Theo is an institutional-grade trading infrastructure platform founded by former quant traders from IMC Trading and Optiver. The platform enables retail users to access sophisticated high-frequency trading and market-making strategies previously available only to Wall Street firms, while providing trading firms with new opportunities to capture alpha through their market expertise with superior capital efficiency. Learn more at theo.xyz

VivaVision Announces Positive Topline Results from Phase 2 Trial of VVN461 for Non-Infectious Anterior Uveitis

  • VVN461, a dual JAK1/TYK2 inhibitor as a non-steroidal anti-inflammatory agent, has met primary endpoints, demonstrating non-inferior efficacy compared to the standard therapy, prednisolone acetate (PA) in treating NIAU
  • Clinically meaningful reductions in inflammation compared to baseline observed as early as Day 3
  • Strong safety profile with no substantial treatment-related adverse events reported

WENZHOU, China, April 25, 2025 /PRNewswire/ — VivaVision Biotech (VivaVision), a clinical-stage, privately held biotechnology company focused on developing innovative treatments for ocular diseases, today announced positive topline results from its phase 2 clinical trial of VVN461, a potent dual JAK1/TYK2 inhibitor for the treatment of Non-Infectious Anterior Uveitis (NIAU) in China.

This is a multicenter, double-masked, randomized, active-controlled, parallel-comparison study conducted at 10 clinical sites in China enrolling 86 subjects with NIAU. Subjects were randomized into three groups (VVN461-1.0%, VVN461-0.5%, and prednisolone acetate-1.0%) and received treatments for 28 days. Prednisolone acetate is the first-line corticosteroid therapy for NIAU.

Both 0.5% and 1% of VVN461 ophthalmic solutions showed non-inferior efficacy compared to active control PA for its primary endpoint: subjects treated with VVN461 had 2 step decrease in ACC grade vs. subjects treated with prednisolone acetate (p <0.001). Note: ACC (anterior chamber cells) were evaluated using SUN grading scale.

Both VVN461 dose groups demonstrated statistically significant and clinically meaningful improvements from baseline across most primary and secondary endpoints. The efficacy of VVN461 groups were comparable to prednisolone acetate group. No substantial treatment-related adverse events were reported, confirming VVN461’s excellent safety profile.

Full data will be reported in future publications in conferences and journals.

“I am very pleased to see that VVN461 showed non-inferior efficacy to prednisolone acetate in the phase 2 clinical trial for NIAU in China. This is a very significant and potentially disruptive progress in treating uveitis.” said Professor. Liu Yang, Director of Ophthalmology at Peking University First Hospital, “We hope that this safe, highly efficacious and accessible non-steroidal medicine, VVN461 would be available to benefit patients in near future.”

Uveitis is the inflammation of uvea which consists of the iris, ciliary body, and choroid. Uveitis affects approximately 3 million patients in China with ~60% classified as NIAU. Uveitis may recur and be chronic, and it is a leading cause of vision loss accounting 10–20% of cases of acquired legal blindness. Treatment of NIAU typically involves the use of topical steroids, which are associated with adverse effects such as increased intraocular pressure, delayed wound healing, and ocular infections. Repeated or chronic use of topical steroids may lead to severe side effects, such as ocular hypertension and cataract. Therefore, the effective control of uveitis inflammation with minimization of side effects is critically needed. VVN461 offers a promising alternative, leveraging its targeted, non-steroidal mechanism to minimize these risks while maintaining anti-inflammatory efficacy.

 VivaVision has scheduled a discussion with Chinese CDE and is planning to request a type C meeting with FDA about phase 3 clinical trials.

About VivaVision Biotech

Founded in 2016, VivaVision Biotech is a clinical-stage pharmaceutical company dedicated to advancing best-in-class therapies with additional investigational drug candidates for ocular diseases. The company’s leading pipeline assets include:

  • VVN461: a non-steroidal dual JAK1/TYK2 immunomodulator for post-operative inflammation after cataract surgery and non-infectious anterior uveitis.
  • VVN001: an investigational treatment for dry eye syndrome.
  • VVN1901: a therapy for targeting neurotrophic keratitis
  • VVN481:  a non-steroidal dual JAK1/TYK2 inhibitor for suprachoroidal delivery to treat posterior/pan-uveitis and posterior inflammatory diseases
  • VVN432: a non-steroidal JAK inhibitor nasal spray for chronic rhinosinusitis (CRS)

In addition to its pipeline, VivaVision is actively engaged in the discovery and development of additional therapies for anterior and posterior segment eye diseases to address unmet patient needs. For more information, please visit www.vivavisionbio.com.

China Media Contact
Ruby SUN
Phone: +86 181-1619-2461
Email: yanyan.sun@vivavisionbio.com

Lionsgate’s ‘Now You See Me: Now You Don’t’ Brings Some of Its Movie Magic to Abu Dhabi in Collaboration with Abu Dhabi’s Creative Media Authority, Abu Dhabi Film Commission and Miral Destinations

ABU DHABI, UAE, April 25, 2025 /PRNewswire/ — Abu Dhabi residents might have captured an exciting glimpse of several scenes from Lionsgate’s highly anticipated movie Now You See Me: Now You Don’t, which wrapped an action-packed 13-day shoot across iconic locations in the capital.

Ariana Greenblatt in Now You See Me: Now You Don’t. Photo Credit: Katalin Vermes
Ariana Greenblatt in Now You See Me: Now You Don’t. Photo Credit: Katalin Vermes

The star-studded cast of the film, including Jesse Eisenberg, Woody Harrelson, Dave Franco, Isla Fisher, Justice Smith, Dominic Sessa, Ariana Greenblatt, with Rosamund Pike, and Morgan Freeman, brought their magic to life across Yas Island and other Abu Dhabi landmarks, including breathtaking locations like Louvre Abu Dhabi, Sheikh Zayed Bridge, and the stunning Liwa desert. When the film hits screens later this year, fans will recognise landmarks including CLYMB and Ferrari World Yas Island, Abu Dhabi, Yas Marina Circuit, W Abu DhabiYas Island, and several Abu Dhabi streets, where thrilling scenes and stunts have been filmed. 

With the assistance of 175 local crew including the team at Epic Films, six UAE based aspiring filmmakers secured internships on set through the talent development arm of the CMA, creative lab. These interns were exposed to on-set learning experiences and were able to apply their creative lab training, whilst seeing how an anticipated international blockbuster shoots on location.

Matt Leonetti, president, physical production for the Lionsgate Motion Picture Group, said: “The Now You See Me films have always taken audiences on global adventures, and this film is no exception. Abu Dhabi’s iconic locations and incredible people will be part of what makes this film so enjoyable and memorable for worldwide audiences.”

Mohamed Dobay, Acting General Director of Creative Media Authority, said: “We are thrilled to have been a key filming location for the Now You See Me: Now You Don’t, seamlessly facilitating and wrapping yet another international Hollywood production in just 13 days across multiple iconic locations. The Lionsgate team benefited not only from Abu Dhabi Film Commission’s financial rebate offering, but also from the support of our key partners, Miral Destinations, facilitating key filming locations and last but not least the expertise of our local crew, led by Epic Films. The involvement of 175 skilled local crew members and six enthusiastic young talents from our community further highlights the growing strength of Abu Dhabi’s film industry. We eagerly anticipate the release this November, when audiences will see some of Abu Dhabi’s most iconic locations come to life on screen.”

Liam Findlay, CEO, Miral Destinations, which manages several of the production locales, said: “At Miral Destinations, we are proud to collaborate with global productions like Lionsgate’s next Now You See Me film, further establishing Yas Island as a premier destination for world-class entertainment and leisure. This accomplishment reflects the seamless cooperation with ADFC and key Abu Dhabi stakeholders, providing unrivalled access to iconic locations on Yas Island and Saadiyat Island. Building on the success of previous international projects, as well as our high-profile Yas Island campaigns featuring A-list ambassadors such as Kevin Hart, Jason Momoa, and Ryan Reynolds, we remain committed to creating unforgettable experiences for both visitors and production partners.”

Set for release this November, the heist thriller film benefits from Abu Dhabi Film Commission’s leading support including a cashback rebate and multi-layered logistical advice. Ruben Fleischer, the superstar director of the blockbuster hits ZombielandVenom, and Uncharted, takes the helm. The film’s screenplay’s is by Seth Grahame-Smith and Michael Lesslie and Paul Wernick & Rhett Reese, with a story by Eric Warren Singer, based on characters created by Boaz Yakin & Edward Ricourt. The film is produced by Bobby Cohen, Alex Kurtzman, and Roberto Orci.

Now You See Me: Now You Don’t is among more than 180 major productions that have used Abu Dhabi as a location in recent years, benefiting from the diversity of its locations, pool of talented professionals, award-winning facilities and generous 35%++ cashback rebate. Alongside hotly anticipated future releases like F1, the major productions include Hollywood hits such as DuneDune: Part Two, Sonic the Hedgehog, and Netflix’s 6 Underground and War Machine as well as franchises Mission: ImpossibleStar Wars and Fast and Furious.

Rosamund Pike in Now You See Me: Now You Don’t. Photo Credit: Katalin Vermes
Rosamund Pike in Now You See Me: Now You Don’t. Photo Credit: Katalin Vermes

 

Director Ruben Fleischer in Now You See Me: Now You Don’t. Photo Credit: Katalin Vermes/Lionsgate
Director Ruben Fleischer in Now You See Me: Now You Don’t. Photo Credit: Katalin Vermes/Lionsgate

 

ViewSonic Earns EcoVadis Silver Rating for Sustainability Excellence

Ranked in the Top 8% of Rated Companies Worldwide for ESG Performance  

BREA, Calif., April 25, 2025 /PRNewswire/ — ViewSonic Corp., a leading global provider of visual and EdTech solutions, has been awarded the EcoVadis Silver rating, placing the company in the 92nd percentile globally and among the top 8% of rated companies for sustainability performance.

ViewSonic Earns EcoVadis Silver Rating for ESG Excellence
ViewSonic Earns EcoVadis Silver Rating for ESG Excellence

This recognition highlights ViewSonic’s significant strides in environmental, social, and governance (ESG) performance. It underscores the company’s commitment to responsible innovation through measurable improvements in sustainable product design, ethical supply chain practices, and global human rights initiatives. 

EcoVadis is a globally recognized sustainability rating platform that evaluates over 130,000 companies across more than 220 industries in 180 countries. Its assessment framework examines 21 criteria grouped into four key themes: Environment, Labor & Human Rights, Ethics, and Sustainable Procurement.

In just one year, ViewSonic advanced from the 57th percentile in 2024 to the 92nd percentile in 2025, signaling substantial progress. This performance not only surpasses the global average but also positions ViewSonic among the world’s leading companies for corporate responsibility and sustainable innovation. 

“Receiving the Silver rating from EcoVadis reaffirms our commitment to building a more sustainable future through thoughtful design and responsible practices,” said Bonny Cheng, Chief Operating Officer at ViewSonic. “We will continue advancing toward our Net-zero goals by enhancing product innovation, improving packaging efficiency, and expanding our use of recycled and responsibly sourced materials, all while working closely with our partners and supply chain to deliver long-term sustainable solutions.”

ViewSonic performed particularly well in the Environment and Labor & Human Rights categories. Its initiatives—ranging from sustainable packaging and energy-efficient product development to comprehensive employee training—demonstrate a well-rounded and integrated approach to corporate responsibility.

In 2024, the company introduced several product-level sustainability initiatives, such as:

  • Developing more compact monitor designs to reduce material usage
  • Integrating universal plug adapters in portable monitors to minimize packaging waste
  • Using cartons made from 80% recycled materials for interactive flat panel displays

Together, these initiatives reflect ViewSonic’s broader commitment to embedding sustainability across its product lifecycle and global operations.  

EcoVadis’ business sustainability ratings are based on international sustainability standards such as the Ten Principles of the UN Global Compact, the International Labour Organization (ILO) conventions, the Global Reporting Initiative (GRI) standards, and the ISO 26000 standard. The ratings provide evidence-based analysis and an actionable roadmap for continuous improvement.

Learn more about ViewSonic’s environmental, social, and governance (ESG) efforts and its path toward a sustainable future:

https://www.viewsonic.com/global/environmental-social-governance/

About ViewSonic

Founded in 1987 in California, ViewSonic is a leading global visual solutions provider with a presence in over 100 countries. The company leverages over 35 years of expertise in visual technology to deliver a comprehensive portfolio of hardware, software, content, and services. ViewSonic offers a wide range of products, with screen sizes spanning from 5 inches to a massive 760 inches. This includes interactive displays, large format displays, LED displays, pen displays, monitors, projectors, SaaS, AI services, interactive content, and more. This innovative ecosystem empowers education, workplaces, and individuals to foster creativity, collaboration, and seamless learning. ViewSonic focuses on designing products that deliver optimal performance and customer satisfaction while integrating sustainable production practices and upholding comprehensive environmental, social, and governance standards. The company’s goal is to enable customers to “See the Difference”. Learn more at www.viewsonic.com.

Atomicwork launches its Universal Agent, bringing Multimodal AI to every employee’s flow of work

This first-of-its-kind Universal Agent eliminates manual work with Voice and Vision AI to make end-users and IT teams 10x more productive

SAN FRANCISCO, April 25, 2025 /PRNewswire/ — Atomicwork today launched its Universal Agent, a new multimodal AI solution that delivers proactive and context-aware support across enterprise applications and devices. The voice-enabled video support drastically reduces ticket volumes by 60% for enterprise service teams like IT, HR, BizOps, and Finance while improving end-user satisfaction by 25%.

Atomicwork seamlessly integrates into employees’ flow of work across business applications on their browsers and devices including collaboration apps like Microsoft Teams, Slack and Email. Atomicwork keeps employees moving – no tickets, no detours, just instant help right in their flow of work – so IT teams can finally ditch the drag of legacy ITSM and ESM tools.

“Legacy ITSM was built for managing tickets. Atomicwork is built to eliminate them,” said Vijay Rayapati, co-founder and CEO of Atomicwork. “With Universal AI at the core, we’re moving from systems of record to systems that act. Context-aware, conversational, and cross-platform in the flow of work – this is how enterprise service delivery should work in an AI-first world.”

Enterprise IT can now give every employee ambient, always-on support

Unlike traditional ITSM tools that expect end-users to recall and describe their issues via email or create tickets on portals, the Universal Agent can proactively engage with end-users wherever they are and in whatever mode they prefer. This includes:

  • Voice AI – Natural, intuitive conversational intelligence to provide step-by-step guidance and instant resolutions.
  • Vision AI – Real-time video and screenshare assistance to diagnose complex IT issues while minimizing back-and-forth and accelerating support.
  • Work AI – Browser agents that execute end to end business processes, improving enterprise productivity and enabling employee self-service at scale.

“Atomicwork is fundamentally reshaping our digital workplace strategy. It enables us to deliver intelligent support at scale – without forcing employees to navigate multiple systems or complex interfaces. This shift from reactive ticketing to proactive support through agentic AI is not just enhancing user experience, it’s driving operational efficiency across our business,” said Karthik Chakkarapani, CIO of Zuora, an Atomicwork customer.

Early adopters have seen nearly 60% drop in ticket volume for complex issues, resolution times reduced by over 80%, and employee satisfaction scores improve by more than 25%.

“We built the Universal Agent to bring the ease and experience of Alexa and Siri to the workplace, with the power and controls that enterprises expect,” said Aparna Chugh, Head of Product at Atomicwork. “Whether it’s fixing your Mac issues, creating a purchase order, or researching a sales prospect – it works across your business apps, understands intent, and gets work done. It’s the AI teammate every employee has been waiting for from their IT team.”

Availability 

The Universal Agent will be available for all Atomicwork’s customers and partners starting today. To book a demo for your team, please sign up at atomicwork.com.

About Atomicwork 

Atomicwork is a modern service management platform, built for the AI era. With agentic AI, it automates routine IT tasks, unifies internal workflows, and delivers instant, contextual ITSM and ESM across Slack, Teams, and the browser – empowering IT teams to focus on strategic initiatives that drive business growth.

Trusted by seasoned CIOs and enterprise IT teams, Atomicwork transforms IT service management while delivering exceptional employee experiences to accelerate business productivity.  Headquartered in San Francisco, Atomicwork serves global enterprises with offices in India and Singapore.

Medit and Graphy Announce Strategic Partnership to Advance Digital Orthodontics

SEOUL, South Korea, April 25, 2025 /PRNewswire/ — Medit, a global leader in digital dentistry solutions, and Graphy, a leading innovator in 3D printing dental materials, have officially announced a strategic partnership to accelerate advancements in the digital orthodontics market.

Medit and Graphy Announce Strategic Partnership to Advance Digital Orthodontics
Medit and Graphy Announce Strategic Partnership to Advance Digital Orthodontics

The partnership brings together Medit’s expertise in intraoral scanning and open digital workflows with Graphy’s groundbreaking material technology, including the world’s first directly 3D-printed clear aligners. The two companies will co-develop next-generation orthodontic solutions that deliver greater speed, accuracy, and efficiency across every stage — from diagnosis to appliance fabrication.

By integrating their technologies, Medit and Graphy aim to enhance user experience for both clinicians and patients, enabling a more seamless and predictable digital orthodontic journey. Further areas of cooperation will be defined as the partnership evolves.

About Medit
Medit Corp. is a global leader in digital dentistry solutions, known for its cutting-edge intraoral scanners and open-platform workflow systems. Headquartered in Seoul, South Korea, Medit develops and supplies the i-Series scanners (including the i700 and i900), which are widely recognized for their speed, accuracy, and ease of use. These scanners are adopted by thousands of clinics and labs across the globe.

Through its cloud-based Medit Link platform, Medit enables seamless integration of scanning, treatment planning, and case management, empowering dental professionals with enhanced flexibility and connectivity in their digital workflows.

Medit’s commitment to open architecture and intuitive software tools has positioned the company at the forefront of the digital dentistry revolution, driving accessibility and innovation across the global market.

About Graphy
Graphy Co., Ltd. is a Korea-based materials science company specializing in high-performance, biocompatible photopolymer resins specifically designed for 3D printing in digital dentistry. With its proprietary oligomer synthesis technology, Graphy independently formulates and manufactures advanced resins that offer superior mechanical properties and stability compared to conventional materials.

Under its flagship brand Tera Harz, Graphy provides material solutions for a wide range of dental applications, including shape memory clear aligners, crowns, bridges, and surgical guides.

Notably, Graphy is the first company in the world to commercialize resin for directly 3D-printed shape memory clear aligners, setting a new standard in functional dental 3D printing and leading the evolution of in-office orthodontic solutions.

 

NYSE Content Advisory: Midday market update + NYSE President congratulates new SEC Chair Paul Atkins

NEW YORK, April 24, 2025 /PRNewswire/ — The New York Stock Exchange (NYSE) President Lynn Martin congratulates Paul Atkins on being sworn in as the new Chairman of the Securities and Exchange Commission. 

 

NYSE Content Advisory: Midday market update + NYSE President congratulates new SEC Chair Paul Atkins

Kristen Scholer delivers the pre-market update on April 24th

  • NYSE President Lynn Martin, in a post on LinkedIn, congratulated SEC Chair Atkins after he was sworn in and expressed appreciation for his longstanding views on the markets.
  • Martin emphasized the NYSE’s strong belief that “regulatory effectiveness and efficiency are central to the attractiveness of our markets,” adding that Chairman Atkins has been making that same argument since 2008.
  • In her post, she wrote that she looks forward to working closely with Atkins and other policymakers in Washington D.C. to “create an environment that ensures our capital markets remain the envy of the world.”
  • Stocks are gaining for a third straight session, extending a two-day rally boosted by a tone down in tariff talk and softer stance toward Federal Reserve Chair Jerome Powell.

Read NYSE President Lynn Martin’s Message Here

Download the NYSE TV App and Subscribe Here

Video – https://mma.prnasia.com/media2/2672662/NYSE_Market_Update_Mid_Day_April_24.mp4

 

Primo’s Taoyuan Facility Achieves PIC/S GMP Certification, Paving the Way for Global Expansion in Nuclear Medicine.

TAIPEI, April 24, 2025 /PRNewswire/ — Primo Biotechnology Co., Ltd. (“Primo”) proudly announces that its Taoyuan pharmaceutical facility has successfully passed inspection by Taiwan Food and Drug Administration (TFDA) and has been award dual certification for PIC/S GMP and GDP. This achievement demonstrates Primo’s dedication to meeting international quality standards for nuclear medicine production and sets the stage for global market growth.

Primo Partners with ABX to Bring PB01 Closer to Taiwan’s Prostate Cancer Market.
Primo Partners with ABX to Bring PB01 Closer to Taiwan’s Prostate Cancer Market.

Since initiating construction in 2023, Primo has focused on establishing a high-efficiency, internationally compliant facility. By integrating advanced and automated production system with over 30 years of the team’s radiopharmaceutical manufacturing experience in medical centers, the company achieved certification in less than two years. This milestone not only strengthens domestic supply capabilities but also accelerates clinical trial progress for new drug candidates and builds international client confidence—paving the way for expanded partnerships in the global markets.

Furthermore, Primo obtained TFDA market approval in April 2025 for Fluorodeoxyglucose F-18 (18F-FDG). This essential radiopharmaceutical for PET/CT imaging plays a key role in diagnosing cancers as well as neurological and cardiac conditions. The commercial launch of F-18 FDG is expected positively contribute to the company’s operational performance.

Beyond F-18 FDG, Primo is actively developing a broad portfolio of radio theranostics radiopharmaceuticals. Recognizing the high technical and regulatory barriers within this field, Primo is also expanding into CRO (Clinical Research Organization) and CDMO (Contract Development and Manufacturing Organization) services. By integrating drug development, pre-clinical trials and manufacturing into its radiopharmaceutical platform. Primo enables close collaboration with partners and supports the acceleration of new drug approvals.

In addition to GMP and GDP certification, Primo is licensed by Taiwan’s Atomic Energy Council for the safe transport of radioactive materials. By following GDP standards, Primo ensures secure and efficient delivery of radiopharmaceuticals. Its strategic location, just 30 minutes from Taoyuan International Airport, provides a logistical edge for global operations.

Securing PIC/S GMP and GDP certifications is a significant milestone for Primo. The company will continue to strengthen its manufacturing and research capabilities, enhancing its competitiveness in the global nuclear medicine market. By partnering with leading medical institutions worldwide, Primo is committed to delivering high-quality diagnostic and therapeutic radiopharmaceuticals to patients worldwide.

About Primo Biotechnology Co., Ltd.

Primo is a leading biotech company specializing in the development and manufacturing of radiopharmaceuticals. With internationally certified facilities, Primo is committed to using precision molecular imaging technology to bring hope and a future to cancer patients. Headquartered in Taipei, the company collaborates with domestic and international partners to drive advancements in precision cancer care. For more information, visit https://primobt.com and follow on Facebook and LinkedIn.